Assignee
XENCOR INC
US·174 granted patents·195 pending applications·4,233 citations·filing 1999–2025
Top patents by PatentIndex Score
369 records- 0199US12466897B2Heterodimeric human IgG1 polypeptides with isoelectric point modificationsXENCOR INC·Filed 2025·Granted Nov 11, 2025·1 cites·1 claims
- 0299US9605084B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Mar 28, 2017·74 cites·16 claims
- 0399US8367805B2Fc variants with altered binding to FcRnXENCOR INC·Filed 2008·Granted Feb 5, 2013·210 cites·3 claims
- 0499US8039592B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2007·Granted Oct 18, 2011·86 cites·19 claims
- 0599US7662925B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2006·Granted Feb 16, 2010·349 cites·15 claims
- 0699US7317091B2Optimized Fc variantsXENCOR INC·Filed 2004·Granted Jan 8, 2008·872 cites·1 claims
- 0799US7276585B2Immunoglobulin variants outside the Fc regionXENCOR INC·Filed 2005·Granted Oct 2, 2007·197 cites·1 claims
- 0898US10793632B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2017·Granted Oct 6, 2020·22 cites·5 claims
- 0998US10584176B2Fc variants with increased affinity for FcγRIIcXENCOR INC·Filed 2018·Granted Mar 10, 2020·21 cites·10 claims
- 1098US10550185B2Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragmentsXENCOR INC·Filed 2017·Granted Feb 4, 2020·29 cites·13 claims
- 1198US10501543B2IL15/IL15Rα heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2017·Granted Dec 10, 2019·13 cites·6 claims
- 1298US10428155B2Trispecific antibodiesXENCOR INC·Filed 2015·Granted Oct 1, 2019·39 cites·5 claims
- 1398US10336818B2Fc variants with altered binding to FcRnXENCOR INC·Filed 2014·Granted Jul 2, 2019·47 cites·5 claims
- 1498US10259887B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2016·Granted Apr 16, 2019·25 cites·25 claims
- 1598US10227410B2Heterodimeric antibodies that bind CD3 and PSMAXENCOR INC·Filed 2016·Granted Mar 12, 2019·36 cites·27 claims
- 1698US9856327B2Heterodimeric antibodies to CD3 X CD123XENCOR INC·Filed 2016·Granted Jan 2, 2018·72 cites·5 claims
- 1798US9803023B2Fc variants with altered binding to FcRnXENCOR INC·Filed 2015·Granted Oct 31, 2017·62 cites·9 claims
- 1898US9701759B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Jul 11, 2017·48 cites·8 claims
- 1998US9650446B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted May 16, 2017·44 cites·9 claims
- 2098US9051373B2Optimized Fc variantsXENCOR INC·Filed 2013·Granted Jun 9, 2015·40 cites·4 claims
- 2198US8383109B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2012·Granted Feb 26, 2013·40 cites·4 claims
- 2298US8362210B2Antibody variants with enhanced complement activityXENCOR INC·Filed 2011·Granted Jan 29, 2013·47 cites·10 claims
- 2398US7657380B2Methods of generating variant antibodies with increased host string contentXENCOR INC·Filed 2004·Granted Feb 2, 2010·169 cites·47 claims
- 2497US12492253B1Anti-human C5 antibodiesXENCOR INC·Filed 2025·Granted Dec 9, 2025·1 cites·1 claims
- 2597US11591401B2Anti-CD28 compositionsXENCOR INC·Filed 2021·Granted Feb 28, 2023·19 cites·5 claims
- 2697US11472890B2Heterodimeric antibodies that bind ENPP3 and CD3XENCOR INC·Filed 2020·Granted Oct 18, 2022·9 cites·4 claims
- 2797US11225528B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·13 claims
- 2897US10787518B2Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2017·Granted Sep 29, 2020·15 cites·19 claims
- 2997US10526417B2Heterodimeric antibodies that bind CD3 and CD38XENCOR INC·Filed 2015·Granted Jan 7, 2020·27 cites·15 claims
- 3097US10184000B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2016·Granted Jan 22, 2019·20 cites·38 claims
- 3197US9605061B2Antibodies with modified isoelectric pointsXENCOR INC·Filed 2014·Granted Mar 28, 2017·43 cites·7 claims
- 3296US11919958B2Anti-CD28 compositionsXENCOR INC·Filed 2021·Granted Mar 5, 2024·9 cites·16 claims
- 3396US11401348B2Heterodimeric Fc variantsXENCOR INC·Filed 2019·Granted Aug 2, 2022·10 cites·5 claims
- 3496US11358999B2IL-12 heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2019·Granted Jun 14, 2022·12 cites·2 claims
- 3596US11254727B2CTLA4-Ig immunoadhesinsXENCOR INC·Filed 2021·Granted Feb 22, 2022·2 cites·4 claims
- 3696US10738133B2Heterodimeric proteinsXENCOR INC·Filed 2017·Granted Aug 11, 2020·9 cites·7 claims
- 3796US9353187B2Optimized FC variants and methods for their generationXENCOR INC·Filed 2013·Granted May 31, 2016·21 cites·9 claims
- 3896US8858937B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2013·Granted Oct 14, 2014·20 cites·9 claims
- 3996US8802823B2Optimized Fc variantsXENCOR INC·Filed 2013·Granted Aug 12, 2014·24 cites·18 claims
- 4096US7315786B2Protein design automation for protein librariesXENCOR INC·Filed 2001·Granted Jan 1, 2008·183 cites·18 claims
- 4196US6403312B1Protein design automatic for protein librariesXENCOR INC·Filed 1999·Granted Jun 11, 2002·321 cites·8 claims
- 4295US12509495B2LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domainsXENCOR INC·Filed 2023·Granted Dec 30, 2025·1 cites·5 claims
- 4395US11919956B2Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3XENCOR INC·Filed 2021·Granted Mar 5, 2024·4 cites·8 claims
- 4495US11655277B2IL-12 heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2022·Granted May 23, 2023·2 cites·1 claims
- 4595US11623957B2Heterodimeric antibodies that bind CD3 and PSMAXENCOR INC·Filed 2016·Granted Apr 11, 2023·9 cites·28 claims
- 4695US11505595B2TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domainsXENCOR INC·Filed 2019·Granted Nov 22, 2022·9 cites·12 claims
- 4795US11225521B2Heterodimeric antibodies that bind somatostatin receptor 2XENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·23 claims
- 4895US11053316B2Optimized antibody variable regionsXENCOR INC·Filed 2018·Granted Jul 6, 2021·7 cites·6 claims
- 4995US10981992B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2018·Granted Apr 20, 2021·6 cites·6 claims
- 5095US10227411B2Modulation of T cells with bispecific antibodies and FC fusionsXENCOR INC·Filed 2016·Granted Mar 12, 2019·17 cites·7 claims
Showing the top 50 of 369 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when XENCOR INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →